Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06238622 · ClinicalTrials.gov registry record · Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

A Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 3
Development phase
1,700
Enrollment target
20
Study locations

NCT06238622: Recruiting Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.

NCT06238622 is a Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 1,700 participants, above the 718-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (137% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06238622, a Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 3
Development phase
1,700 participants
Enrollment target
20
Study locations

Study Summary

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.

Conditions Studied

Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis

Interventions

  • DRUG Nerandomilast

Study Locations (20)

California

  • University of Southern California - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • University of California Los Angeles - Los Angeles
  • University of California Davis - Sacramento

Florida

  • St. Francis Medical Institute - Clearwater
  • University of Florida - Gainesville
  • Clinical Research Specialists LLC - Kissimmee - Kissimmee
  • Advanced Pulmonary Research Institute - Loxahatchee Groves

Georgia

  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead - Atlanta
  • The Emory Clinic - Atlanta

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • University of Arizona - Tucson

Colorado

  • National Jewish Health - Denver

Connecticut

  • Yale University School of Medicine - New Haven

Delaware

  • Christiana Hospital - Newark

Trial Details

FieldValue
Enrollment Target 1,700 participants
Start Date 2024-05-06
Est. Completion 2027-05-05
Phase Phase 3
Boehringer Ingelheim

515 total trials

What NCT06238622 shows while recruiting

NCT06238622 is an interventional study that assigns participants to a tested intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus, above the 718-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (137% higher).

The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Nerandomilast is the first listed.

NCT06238622 names 20 study sites across 13 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06238622 about?

NCT06238622 is a clinical study titled "A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast". This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with ...

What is the current status of trial NCT06238622?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,700 participants. The study started on 2024-05-06. Estimated completion is 2027-05-05.

What conditions does trial NCT06238622 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.

What interventions are being tested in trial NCT06238622?

The interventions under investigation include: Nerandomilast (DRUG).

Who is sponsoring clinical trial NCT06238622?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06238622 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06238622's enrollment target sits among peer trials

1,700 4th of 51 higher than 48 of 51 other Idiopathic Pulmonary Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04321200 · 1,700 participants

    PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability

  • NCT07284901 · 1,700 participants · Phase 3

    Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • NCT07304531 · 1,705 participants

    First To Know Pregnancy Test - Clinical Evaluation Protocol

  • NCT05303636 · 1,710 participants · Phase 4

    LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06238622

Source: ClinicalTrials.gov NCT06238622, the US trial registry maintained by the National Library of Medicine. NCT06238622 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.